Learning Technologies Gr Stock (OTC: LTTHF)

Latest news for Learning Technologies Gr (OTC:LTTHF) Stock

Learning Technologies Gr

Learning Technologies Group PLC, along with its subsidiaries, offers a wide range of e-learning services and technologies to corporate and government clients. The company operates in two reportable segments: the Software and Platforms and the Content and Services. Geographically, it operates in the United Kingdom, Mainland Europe, North America, Asia Pacific and the Rest of the World. The company earns maximum revenue from North America.

News

Penny Stocks

Small Cap

LTTHF

GP Strategies Shares Soar After Being Acquired By Learning Technologies For ~$394M

LEARNING TECHS GROUP PLC by Learning Technologies Group PLC

Learning Technologies Group PLC

AVAV

UAVS

VISL

Pentagon Says Has No Evidence That Drones Over New Jersey Are Coming From A Foreign Entity Or Adversary

Citigroup analyst Joanne Wuensch maintains Integer Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITGR#NYSE">ITGR</a>) with a Neutral and raises the price target from $130 to $145.

Price Target

Analyst Ratings

ITGR

Citigroup Maintains Neutral on Integer Holdings, Raises Price Target to $145

KVHI

KVH Announces Sale Agreements For Rhode Island Properties Valued At $12M And $10M Share Buyback Program To Support Strategic Opportunities And Shareholder Value

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) and Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), on Wednesday, announced long-term results from the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42440199/lynparza-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-ca" rel="noreferrer noopener">OlympiA Phase 3 trial</a>.
The trial showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) for people with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42363652/soon-after-approval-for-lung-cancer-astrazenecas-cancer-drug-imfinzi-goes-under-fda-priority-review-for-bladder-cancer" rel="noreferrer noopener">After Lung Cancer Approval, AstraZeneca&#8217;s Imfinzi Goes Under FDA Priority Review For Bladder Cancer</a>
At a median follow-up of 6.1 years (maximum 9.6 years) in eligible patients, who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, Lynparza reduced the risk of death by 28% versus placebo.
In addition,&nbsp;87.5% of patients treated with&nbsp;Lynparza remained alive versus 83.2% of those on placebo.
Lynparza&nbsp;also demonstrated sustained and clinically meaningful improvements in the primary and secondary endpoints of IDFS and DDFS.
Lynparza reduced the risk of invasive breast cancer recurrence, second cancers, or death by 35% and reduced the risk of distant disease recurrence or death by 35% versus placebo.
The benefit with Lynparza was consistent across all key subgroups, including patients with high-risk, hormone-receptor-positive disease.
Recently, Merck&nbsp;announced topline data from the Phase 3&nbsp;KEYLYNK-001 trial of Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza, with or without bevacizumab, as a first-line treatment for BRCA non-mutated advanced epithelial ovarian cancer met its primary endpoint of <a target="_blank" href="https://www.benzinga.com/24/12/42393128/merck-reveals-mixed-data-from-keytrudalynparza-regime-in-ovarian-cancer" rel="noreferrer noopener">progression-free survival</a>.
The Keytruda plus Lynparza regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for these patients compared to chemotherapy alone.
The study did not reach its secondary endpoint of overall survival. The role of keytruda in the intention-to-treat population remains uncertain at this time.
Price Action: MRK stock is up 0.11% at $101.11, and AZN stock is up 0.47% at $67.50 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42442160/eli-lillys-investigational-cancer-drug-cuts-risk-of-death-by-38-in-breast-cancer-patients" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients

Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $283 to $310.

PODD

Citigroup Maintains Buy on Insulet, Raises Price Target to $310

Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and raises the price target from $81 to $83.

Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $83

On Wednesday, AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42436193/anaptys-announces-phase-2b-trial-of-anb032-a-btla-agonist-did-not-meet-primary-or-secondary-endpoi" rel="noreferrer noopener">(AD) or eczema</a>.
&#8220;While ANB032 was safe and well tolerated, we&#8217;re disappointed by these efficacy results in AD and will discontinue further investment in this asset. Moving forward, our resources and capital will be focused on the rest of our exciting autoimmune portfolio,&#8221; said Daniel Faga, president and chief executive officer of Anaptys.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39891711/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lillys-anal" rel="noreferrer noopener">AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly&#8217;s: Analyst</a>
&#8220;We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase 2b rheumatoid arthritis data in February 2025 and top-line Phase 2 ulcerative colitis data in Q1 2026, followed by Phase 1b data from our two additional programs.&#8221;
The study enrolled 201 patients with a mean baseline EASI score of 27.3 in the U.S., Canada, Europe, Australia and New Zealand, who were either biologics naïve (n=168) or biologics experienced (n=33), defined as having received treatment with dupilumab or other IL-13 therapies.
Patients were randomized to receive either 100mg of subcutaneous ANB032 every four weeks (Q4W), 400mg every four weeks (Q4W), 400mg every two weeks (Q2W), or placebo for 12 weeks.
The primary and secondary endpoints were assessed at Week 14.
Regardless of prior treatment experience, ANB032 did not meet the primary endpoint of the proportion of patients who achieved at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI-75), or any of the secondary endpoints at Week 14, including EASI-90, mean change in baseline EASI or a 4-point reduction in itch severity versus placebo.
Absolute response rates on key endpoints in patients treated with ANB032 approached the minimum target product profile with durable off-drug responses; however, higher placebo rates outside of the historical norm, particularly in the U.S., were observed.
ANB032 was well tolerated across all doses, and no safety signals were observed.
Price Action: ANAB stock is down 36.3% at $14.72 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/12/42439950/dental-product-supplier-patterson-companies-goes-private-in-4-1-billion-deal" target="_blank" rel="noreferrer noopener">Dental Product Supplier Patterson Companies Goes Private In $4.1 Billion Deal</a></li>
</ul>

Movers

Trading Ideas

ANAB

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

<a href="https://wwd.com/pop-culture/new-fashion-releases/simone-rocha-crocs-collection-release-info-1236289939/">Crocs</a> is striving to become as prominent in accessories as it is in footwear.
WWD has learned that <a href="https://wwd.com/tag/crocs/">Crocs</a> has signed a multiyear licensing agreement with Concept One Accessories, the New York-based accessory firm, which will produce backpacks, handbags, totes, waist packs, cross-body bags and wallets.&nbsp;
<a href="https://wwd.com/business-news/human-resources/crocs-cfo-brand-president-michelle-poole-retires-1236160864/">Crocs</a> launched three molded-style bags this past summer in their brick-and-mortar and online stores, but will vastly build an accessories offer with the help of Concept One. Molded-style bags are those created using a mold for consistent design and details that can be hard to create by hand.
According to a statement from the two companies: "Similar to the brand's iconic Classic Clogs, the bags are uniquely designed to be a canvas for self-expression, with holes designed into the molds for adding Jibbitz charms. Concept One will be working with Crocs to expand the line into additional silhouettes, as well as using some of the brand's most popular prints and glitter finishes from its iconic footwear." Jibbitz are charms used for footwear to create individual looks.
"Crocs has been synonymous with molded footwear for years and has evolved into a lifestyle brand," Sam Hafif, chief executive officer of Concept One, said in a statement. "We began discussing a license agreement with Crocs earlier this year, and together shared a vision of having Crocs become as iconic in the bag category as it is in the footwear category.&nbsp;We love the core brand and are excited to work together to create even more product that enables self-expression."
Hafif added that the bags will be carried at Crocs retail stores, on crocs.com and will also be offered for wholesale distribution beginning early next year.
Founded in 1999, Concept One Accessories provides fashion accessories across all channels of distribution and has offices in New York, Mexico, the U.K. and China along with distribution partnerships in Canada, South Africa, Australia, Central and South America and the Middle East. The company has been steadily signing licensing deals, including most recently with <a href="https://wwd.com/tag/jason-wu/">Jason Wu</a>&nbsp;for an "aspirational" collection of handbags and small leather goods. The designer had been handling the production of his bags in-house and has decided to shift to licensing. Also this year, Concept One signed a deal to produce a line of soft accessories for&nbsp;<a href="https://wwd.com/tag/french-connection/">French Connection</a>, the contemporary lifestyle brand. In the last several years, the company has also partnered up with Tommy Bahama, FUBU, New Balance, Brooks Brothers, Smoke Rise and Fred Segal.
Crocs, based in Broomfield, Colo., is a leader in casual footwear. The company's brands include Crocs and HeyDude.
<a href="https://wwd.com/accessories-news/handbags/crocs-building-accessories-offering-through-licensing-deal-with-concept-one-1236760021/#:~:text=Crocs%20is%20striving%20to%20become,cross%2Dbody%20bags%20and%20wallets" title="https://wwd.com/accessories-news/handbags/crocs-building-accessories-offering-through-licensing-deal-with-concept-one-1236760021/#:~:text=Crocs%20is%20striving%20to%20become,cross%2Dbody%20bags%20and%20wallets">https://wwd.com/accessories-news/handbags/crocs-building-accessories-offering-through-licensing-deal-with-concept-one-1236760021/#:~:text=Crocs%20is%20striving%20to%20become,cross%2Dbody%20bags%20and%20wallets</a>.

CROX

'Crocs Building Accessories Offering Through Licensing Deal With Concept One' - WWD

BofA Securities analyst Ross Fowler initiated coverage on California Water Service Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWT#NYSE">CWT</a>) with a Buy rating and price forecast of $57, which<a target="_blank" href="https://www.benzinga.com/quote/CWT/analyst-ratings" rel="noreferrer noopener"> implies an upside potential of 17%.</a>
Per Fowler, the company is currently trading at the lowest valuation compared to other U.S. water utilities, even though its earnings outlook is improving and it has significant capital investment plans for 2025-2028. California Water also has extra financial capacity to increase capital spending if needed.
The analyst prefers a value-focused strategy within the water utility sector, believing that the premium prices for these stocks will eventually align with those of electric and gas utilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42444498/bank-of-america-raises-bullish-outlook-on-us-brokers-exchanges-alternative-investments-3-top-picks-for-2025" rel="noreferrer noopener">Bank Of America Raises Bullish Outlook On US Brokers, Exchanges, Alternative Investments: 3 Top Picks For 2025</a>
The analyst writes, California Water stands out as the most affordable U.S. water utility, trading at an 8% discount to the water utility sector and 19% below its closest competitor, American States Water Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWR#NYSE">AWR</a>).
The analyst notes that the improved earnings outlook and potential capital spending growth could drive the stock&#8217;s performance.
Fowler forecasts California Water&#8217;s EPS for 2025, 2026, and 2027 to be $2.34, $2.63, and $2.85, respectively, with slight deviations from consensus (-1.4%, +5.6%, -1.4%).
California Water&#8217;s 2024 rate case filing in California reveals significant deferred investments, with capital spending plans for 2025-2027 nearly double those from 2022-2024.
While there is a higher risk of disallowances, the analyst conservatively assumes 80% recovery (compared to 90%+ in other California cases), which still leads to an estimated 8%-10% EPS growth and over 10% growth in the rate base through 2027.
Per Fowler, cash flow is expected to improve due to the 2021 GRC, and the company will likely need $50 million to $100 million annually in equity to maintain about 55% equity capitalization, which is above the current authorized level.
Price Action: CWT shares are trading higher by 0.14% to $48.71 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42421528/trumps-tariff-storm-3-survival-strategies-us-companies-are-using-to-fight-back" target="_blank" rel="noreferrer noopener">Trump&#8217;s Tariff Storm: 3 Survival Strategies US Companies Are Using To Fight Back</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Equities

Initiation

Markets

This Water Utility Stock Trades At A Discount: Analyst

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $85 to $91.

DXCM

Citigroup Maintains Buy on DexCom, Raises Price Target to $91

Berenberg analyst Harry Goad maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Buy and raises the price target from $224 to $240.

FERG

Berenberg Maintains Buy on Ferguson Enterprises, Raises Price Target to $240

Econ #s

USA Federal Budget Balance For November -367.0B Vs -349.0B Est.; -257.0B

Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Neutral and lowers the price target from $37 to $35.

Citigroup Maintains Neutral on Baxter Intl, Lowers Price Target to $35

Bernstein analyst Chad Dillard maintains Trimble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) with a Outperform and raises the price target from $82 to $85.

TRMB

Bernstein Maintains Outperform on Trimble, Raises Price Target to $85

In the last three months, 11 analysts have published ratings on Essential Props Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.84, along with a high estimate of $40.00 and a low estimate of $32.00. Witnessing a positive shift, the current average has risen by 6.35% from the previous average price target of $33.70.
<img src="https://www.benzinga.com/files/images/story/2024/1733943696_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Essential Props Realty among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.25</td>
<td>$32.00</td>
</tr>
<tr>
<td>Sheila McGrath</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$34.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Essential Props Realty. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Essential Props Realty compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Essential Props Realty's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Essential Props Realty's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EPRT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Essential Props Realty analyst ratings.</a>
<h2>About Essential Props Realty</h2>
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses.
<h3>Essential Props Realty's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Essential Props Realty's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 27.79%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Essential Props Realty's net margin is impressive, surpassing industry averages. With a net margin of 41.85%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Essential Props Realty's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.52% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Essential Props Realty's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.91% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.69.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EPRT

Where Essential Props Realty Stands With Analysts

During the last three months, 8 analysts shared their evaluations of Mohawk Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $159.0, a high estimate of $196.00, and a low estimate of $134.00. Observing a 0.47% increase, the current average has risen from the previous average price target of $158.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1733943683_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Mohawk Industries's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$141.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Michael Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$134.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Overweight</td>
<td>$196.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Deepa Raghavan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Mohawk Industries. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Mohawk Industries compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Mohawk Industries's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Mohawk Industries's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MHK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Mohawk Industries analyst ratings.</a>
<h2>Delving into Mohawk Industries's Background</h2>
Mohawk Industries Inc manufactures a wide range of flooring products, including carpets, rugs, ceramic tile, laminate, wood, luxury vinyl tile, and vinyl flooring. Its operating segments include Global Ceramic, Flooring North America, and Flooring Rest of the World. The company generates maximum revenue from the Global Ceramic segment. Geographically, it derives a majority of its revenue from the United States.
<h3>Mohawk Industries's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Mohawk Industries's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -1.7% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.96%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Mohawk Industries's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.09%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Mohawk Industries's ROA stands out, surpassing industry averages. With an impressive ROA of 1.22%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Mohawk Industries's debt-to-equity ratio is below the industry average at 0.33, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Mohawk Industries: 8 Analysts Share Their Views

11 analysts have shared their evaluations of Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $279.91, a high estimate of $317.00, and a low estimate of $234.00. Marking an increase of 14.16%, the current average surpasses the previous average price target of $245.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1733943674_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Insulet by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lawrence Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$305.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$304.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$234.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$317.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Insulet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Insulet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Insulet's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>About Insulet</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Understanding the Numbers: Insulet's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Insulet's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 25.7%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Insulet's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 14.25%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Insulet's ROE stands out, surpassing industry averages. With an impressive ROE of 7.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Insulet's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.62% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Insulet's debt-to-equity ratio stands notably higher than the industry average, reaching 1.25. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 11 Analyst Evaluations For Insulet

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $98 to $107.

Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $107

Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $79.73, with a high estimate of $88.00 and a low estimate of $76.00. This current average has increased by 6.88% from the previous average price target of $74.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1733943641_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Agree Realty is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Gorman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>RJ Milligan</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Upal Rana</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Agree Realty. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Agree Realty compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Agree Realty's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agree Realty analyst ratings.</a>
<h2>Get to Know Agree Realty Better</h2>
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-leading tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
<h3>A Deep Dive into Agree Realty's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Agree Realty's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 12.81%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Agree Realty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 27.48%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Agree Realty's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.84%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.52%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Agree Realty's debt-to-equity ratio is below the industry average. With a ratio of 0.52, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Agree Realty Stands With Analysts

6 analysts have shared their evaluations of Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $179.0, a high estimate of $193.00, and a low estimate of $170.00. This current average reflects an increase of 7.57% from the previous average price target of $166.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1733943622_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Masimo is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$193.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$170.00</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Masimo. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Masimo compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Masimo's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Masimo's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MASI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Masimo analyst ratings.</a>
<h2>About Masimo</h2>
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Financial Insights: Masimo</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Masimo displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 5.37%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 1.94%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Masimo's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.69%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Masimo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.33%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.59, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MASI

Expert Ratings For Masimo

Learning Technologies Group reports FY results

Learning Technologies Group plc (LTTHF) Q4 2023 Earnings Call Transcript

Learning Technologies Group plc (LTTHF) Q2 2024 Earnings Call Transcript

Learning Technologies reports steady performance amid economic challenges

<ul>
	<li>GP Strategies Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPX#NYSE">GPX</a>), a workforce transformation solutions provider, has <a href="https://www.benzinga.com/pressreleases/21/07/n22002181/gp-strategies-agrees-to-merge-with-learning-technologies-group-creating-one-of-the-worlds-largest-">agreed to be acquired</a> by London-based&nbsp;Learning Technologies Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LTTHF#OTC">LTTHF</a>) in a $394 million transaction.</li>
	<li>Learning Technologies will pay $20.85&nbsp;per GP Strategies share in cash.</li>
	<li>The transaction represents a premium of 32% over the closing price on&nbsp;July 14, 2021.</li>
	<li>Upon closing of the deal, GP Strategies will become a division of Learning Technologies Group and its shares will no longer be listed on the NYSE.</li>
	<li>This transaction is expected to be completed during the fourth quarter of 2021.</li>
	<li>GP Strategies&#39; largest shareholder Sagard Capital Partners Management supports this transaction.</li>
	<li>Price action: GPX shares are trading higher by 28.7% at $20.29 on the last check Thursday.</li>
</ul>

Comments

Learning Technologies Gr

News

Latest news for Learning Technologies Gr (OTC:LTTHF) Stock

Thursday, July 15, 2021

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga